Stock Based Activity | 11. Stock Based Activity Common stock issuance In February 2019, the Company conducted a public offering 7,733,750 shares of its common shares including 1,008,750 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares to cover over-allotments, at a public offering price of $2.10 per share. The net proceeds to the Company from this offering are $14,867, after deducting underwriting discounts and commissions and other offering expenses. Proceeds from the offering will provide capital to fund the growth of our business, new products, sales and marketing efforts, working capital, and for general corporate purposes. On February 1, 2019, the Company issued 17,652 shares of common stock issued to certain directors of the Company as compensation for services rendered. The shares had an aggregated value of approximately $44. Restricted common stock The following table summarizes restricted stock activity during the six months ended June 30, 2019: Unvested Shares Fair Value Weighted Average Grant Date Fair Value Balance, December 31, 2018 598,370 $ 592 1.63 Granted 24,216 $ 76 3.14 Vested (8,072 ) $ (331 ) Issued Balance, June 30, 2019 614,514 $ 337 0.59 Prior to January 1, 2019, the Company issued 854,592 shares of restricted common stock to the Company’s Chief Executive Officer and members of the board valued at $1,413, of which 256,222 shares have vested, and $820 has been recognized as an expense. During the six months ended June 30, 2019, the Company issued an additional 24,216 shares of restricted stock to members of the board of directors. These shares vest through November 2019 over 3 equal periods, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was $76 based on the market price of our common stock at $3.14 per share on the date of grant, which will be amortized through November 2019. During the six months ended June 30, 2019, the Company and the Chief Executive Officer entered into an agreement extending the vesting of the 392,002 shares that were scheduled to vest on June 29, 2019 to August 30, 2019. The total fair value of restricted common stock vesting during six months ended June 30, 2019 was $331 and is included in general and administrative expenses in the accompanying statements of operations. As of June 30, 2019, the amount of unvested compensation related to issuances of restricted common stock was $337, which will be recognized as an expense in future periods as the shares vest. Stock options Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Terms (Years) Aggregate Intrinsic Value Outstanding at December 31, 2018 3,674,236 $ 2.16 Granted 877,330 $ 2.70 Exercised - $ - Unvested Forfeited or expired 91,000 $ 2.21 Vested Forfeited or expired 95,000 $ 4.75 Outstanding at June 30, 2019 4,365,566 $ 2.22 8.45 $ 6,992 Exercisable at June 30, 2019 1,296,762 $ 2.30 6.85 $ 2,081 During the six months ended June 30, 2019, the Company approved options to be issued pursuant to Reed’s 2017 Incentive Compensation Plan to certain current employees totaling 794,000. One half of these options vest annually over a four-year vesting period; the other half of these options will vest based on performance criteria to be established by the board. In addition, during the six months ended June 30, 2019, the Company granted options to purchase 83,330 shares of common stock to certain consultants and former employees. Options granted to consultants and former employees vest at various periods. The stock options are exercisable at a price ranging from $2.33 to $3.37 per share and expire in ten years. Total fair value of these options at grant date was approximately $1,413, which was determined using the Black-Scholes-Merton option pricing model with the following average assumption: stock price ranging from $2.33 to $3.37 per share, expected term of seven years, volatility of 61%, dividend rate of 0% and risk-free interest rate ranging from 1.75% to 2.60%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. The Company determined that the options had a fair value of $1,413 which will be amortized in future periods through June 30, 2023. During the six months ended June 30, 2019, the Company recognized $854 of compensation expense relating to outstanding stock options. As of June 30, 2019, the amount of unvested compensation related to stock options was approximately $3,133 which will be recorded as an expense in future periods as the options vest. The aggregate intrinsic value was calculated as the difference between the closing market price as of June 30, 2019, which was $3.78, and the exercise price of the outstanding stock options. Common stock purchase warrants The following table summarizes warrant activity for the six months ended June 30, 2019: Shares Weighted- Weighted- Aggregate Intrinsic Value Outstanding at December 31, 2018 6,897,277 $ 2.06 2.42 $ 1,447 Granted Exercised 276,995 $ 2.09 Forfeited or expired Outstanding at June 30, 2019 6,620,282 $ 2.06 1.96 $ 11,829 Exercisable at June 30, 2019 6,620,282 $ 2.06 1.96 $ 11,829 During the six months ended June 30, 2019, warrants to acquire 276,995 shares of common stock were exercised, including 81,710 warrants that were exercised on a cashless basis, resulting in the issuance of 219,891 shares of common stock. Aggregate proceeds to the Company were $364. The intrinsic value was calculated as the difference between the closing market price as of June 30, 2019, which was $3.78, and the exercise price of the Company’s warrants to purchase common stock. |